Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
about
SchizophreniaRNA sequencing reveals a slow to fast muscle fiber type transition after olanzapine infusion in ratsClozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cellsMorbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs.Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances.Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.The appropriateness of routine medication treatment for schizophrenia.Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study.Schizophrenia (maintenance treatment).Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Making room for mental health in the medical homeWeight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.The nature of relapse in schizophrenia.A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trialA new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophreniaBehavioral and metabolic effects of the atypical antipsychotic ziprasidone on the nematode Caenorhabditis elegans.STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label studyIncomplete response in late-life depression: getting to remissionCan metformin undo weight gain induced by antipsychotics?Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.Critical appraisal of lurasidone in the management of schizophrenia.Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in miceAtypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studiesInhibition of mouse brown adipocyte differentiation by second-generation antipsychoticsAntipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonAnthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural populationAn Economic Evaluation of a Weight Loss Intervention Program for People with Serious Mental Illnesses Taking Antipsychotic MedicationsImproving lifestyle interventions for people with serious mental illnesses: Qualitative results from the STRIDE studyBehavioral interventions for antipsychotic induced appetite changes.Reduced arterial compliance in patients with psychiatric diagnoses.Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordTen-year trends in quality of care and spending for depression: 1996 through 2005.
P2860
Q24596536-EC1D2D53-C318-48FB-A0A8-953CD5FA7976Q27309270-1496959A-4747-46CE-85C2-D07D9047E39AQ28488537-762CDF01-C987-4B4D-8A5D-9211C97E3E75Q30490094-6635164C-D1A4-485A-B48C-4763B9A6F59BQ33606810-036737C0-B42E-4D57-9474-8599A9650E0CQ33718801-04430340-F6AD-4E36-BA7A-4EE51481CC13Q33942644-24F91D54-832C-4C69-A4E3-B8D84D120DA9Q33950877-3D55C1DB-0622-49CD-9FAC-91687D22DE22Q33966340-7FD826F4-CBF2-41D6-B625-ED2F6BAAA466Q34010697-EF508E34-60B3-43CE-A9F9-87283A755CCEQ34054063-81FE0B3B-25A9-4916-8EF0-42C89AA4180DQ34371307-B3634B42-150F-4A5A-B0D3-73E934856DF3Q34486175-62C332CA-2CAB-4529-A945-7D0095E363E2Q34523972-811FC50B-9016-4076-A587-81D12705A3DFQ34543946-09710401-2CC6-40CB-B4D2-B33ABF99A386Q34581127-CF442A0D-4909-4A84-81FB-F2C817B40BA9Q34595181-22BF7541-5883-40E7-A892-4123B09968C9Q34604314-7EAC3202-9DB5-4D86-92D8-BAF869D9B3A9Q34655540-61B2713A-089F-4F80-BD83-434CAAB40B3EQ34999318-B534610E-0C2D-410C-8D7F-E46B476B59B2Q35001376-47553841-9172-4B79-99FB-A661ABA6E685Q35115972-4C60912D-8DC4-46E8-89E1-5A00DB00B7F6Q35156543-05B75505-4DED-43C8-8D9E-2EBDF9BFCAD0Q35191252-63BB6FB4-499A-4A9E-A894-27AB7E28A551Q35237063-AEB42363-F938-4CAD-8EC1-F8B8736C598DQ35247085-60C7308B-9567-4C5C-A871-1A919E495390Q35693061-75364F90-A62A-4F16-ABC7-72028E18677CQ35939685-70A39661-3D0E-449B-9CA1-C8178E7E12F1Q35982317-DC5B0878-1567-43FA-B990-534D76398F0FQ36205791-900398F7-07CF-443F-B1B9-883F24C4AE6AQ36230583-BC076A1A-1979-43E2-BAF5-96CFC3B1B274Q36301864-B0ED8B04-312D-4277-A239-DAFC83AB3670Q36325431-E611871B-C47A-4710-9201-6A84A77749BEQ36420353-17E8B8BA-5B56-48CC-97BA-A80AEB022CD1Q36441253-1FBED37C-DE12-4F19-A3A1-F189F0E904BBQ36510504-5075BAD6-C9B9-48CF-8636-6921340FFF6FQ36651040-13773318-23CA-42BB-9E83-8F326776E055Q36676029-F67214D6-5794-4421-9DDF-E7AA4C37C889Q36921831-102A6C07-8E2A-4982-8C4E-51D8985AD222Q36924338-0420D37D-B7BA-4FCF-AAE5-4DBFD7BC34D9
P2860
Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Metabolic considerations in th ...... : a review of recent evidence.
@ast
Metabolic considerations in th ...... : a review of recent evidence.
@en
Metabolic considerations in th ...... : a review of recent evidence.
@nl
type
label
Metabolic considerations in th ...... : a review of recent evidence.
@ast
Metabolic considerations in th ...... : a review of recent evidence.
@en
Metabolic considerations in th ...... : a review of recent evidence.
@nl
prefLabel
Metabolic considerations in th ...... : a review of recent evidence.
@ast
Metabolic considerations in th ...... : a review of recent evidence.
@en
Metabolic considerations in th ...... : a review of recent evidence.
@nl
P1476
Metabolic considerations in th ...... : a review of recent evidence.
@en
P2093
John W Newcomer
P478
68 Suppl 1
P577
2007-01-01T00:00:00Z